DARIFENACIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C28H30N2O2
Molecular Weight	426.55
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C4=CC=CC=C4)C5=CC=CC=C5

InChI

InChIKey=HXGBXQDTNZMWGS-RUZDIDTESA-N

InChI=1S/C28H30N2O2/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26/h1-12,19,25H,13-18,20H2,(H2,29,31)/t25-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C28H30N2O2
Molecular Weight	426.55
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021513s010lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/9121347

Darifenacin is a selective muscarinic receptor M3 antagonist which was approved by FDA for the treatment of overactive bladder.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Muscarinic acetylcholine receptor M3 160 Target ID: P20309 Gene ID: 1131.0 Gene Symbol: CHRM3 Target Organism: Homo sapiens (Human) Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021513s010lbl.pdf	Antagonist 2849		0.33 nM [Kd]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Overactive bladder 39 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021513s010lbl.pdf	Palliative		Approved 8583	ENABLEX Approved Use ENABLEX® (darifenacin) extended-release tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Launch Date 2004

C_max

Value	Dose	Co-administered	Analyte	Population
2.01 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021513s010lbl.pdf	7.5 mg 1 times / day steady-state, oral dose: 7.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DARIFENACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5.76 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021513s010lbl.pdf	15 mg 1 times / day steady-state, oral dose: 15 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DARIFENACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
29.24 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021513s010lbl.pdf	7.5 mg 1 times / day steady-state, oral dose: 7.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DARIFENACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
88.9 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021513s010lbl.pdf	15 mg 1 times / day steady-state, oral dose: 15 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DARIFENACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
12.43 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021513s010lbl.pdf	7.5 mg 1 times / day steady-state, oral dose: 7.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DARIFENACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
12.05 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021513s010lbl.pdf	15 mg 1 times / day steady-state, oral dose: 15 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DARIFENACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021513s010lbl.pdf	7.5 mg 1 times / day steady-state, oral dose: 7.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DARIFENACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021513s010lbl.pdf	15 mg 1 times / day steady-state, oral dose: 15 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DARIFENACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex_biopharmr.pdf	unhealthy, 57.6 Health Status: unhealthy Age Group: 57.6 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex_biopharmr.pdf	Disc. AE: Constipation, Dry mouth... AEs leading to discontinuation/dose reduction: Constipation (1%) Dry mouth (1%) Nervous system disorder NOS (0.6%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex_biopharmr.pdf
7.5 mg 1 times / day multiple, oral Recommended Dose: 7.5 mg, 1 times / day Route: oral Route: multiple Dose: 7.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex_biopharmr.pdf	unhealthy, 57.6 Health Status: unhealthy Age Group: 57.6 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex_biopharmr.pdf	Disc. AE: Heart block AV second degree... AEs leading to discontinuation/dose reduction: Heart block AV second degree (0.3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex_biopharmr.pdf

AEs

AE	Significance	Dose	Population
Nervous system disorder NOS	0.6% Disc. AE	15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex_biopharmr.pdf	unhealthy, 57.6 Health Status: unhealthy Age Group: 57.6 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex_biopharmr.pdf
Constipation	1% Disc. AE	15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex_biopharmr.pdf	unhealthy, 57.6 Health Status: unhealthy Age Group: 57.6 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex_biopharmr.pdf
Dry mouth	1% Disc. AE	15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex_biopharmr.pdf	unhealthy, 57.6 Health Status: unhealthy Age Group: 57.6 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex_biopharmr.pdf
Heart block AV second degree	0.3% Disc. AE	7.5 mg 1 times / day multiple, oral Recommended Dose: 7.5 mg, 1 times / day Route: oral Route: multiple Dose: 7.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex_biopharmr.pdf	unhealthy, 57.6 Health Status: unhealthy Age Group: 57.6 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex_biopharmr.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252	inhibitor 2438	substrate 1388 inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153	P-gp 2052 BCRP 697 MRP 9

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021513lbl.pdf@page=6 Page: 6.0	no
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021513lbl.pdf@page=6 Page: 6.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex_biopharmr.pdf@page=23 Page: 23.0	yes [IC50 2 uM]	yes (co-administration study) Comment: Label: Mean Cmax and AUC of imipramine, a CYP2D6 substrate, were increased 57% and 11 70%, respectively, in the presence of steady-state darifenacin; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex_biopharmr.pdf@page=23 Page: 23.0
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex_biopharmr.pdf@page=23 Page: 23.0	yes [IC50 5 uM]	weak (co-administration study) Comment: Label: Darifenacin coadministered with a single oral dose of 15 midazolam 7.5 mg resulted in 17% increase in midazolam exposure Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex_biopharmr.pdf@page=23 Page: 23.0

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex_biopharmr.pdf#page=22 Page: 22.0	major	yes (co-administration study) Comment: Label: Darifenacin exposure following 30 mg once daily at steady state was 33% higher in the presence of the potent CYP2D6 inhibitor paroxetine; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex_biopharmr.pdf#page=22 Page: 22.0
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex_biopharmr.pdf#page=46 Page: 46.0	major	yes (co-administration study) Comment: Label: Mean steady state darifenacin exposure in EM subjects was about 5 fold higher when ketoconazole was co-administered; mean Cmax and AUC of 25 darifenacin following 30 mg once daily dosing at steady state were 128% and 95% higher, 26 respectively, in the presence of erythromycin; Coadministration of fluconazole and darifenacin 30 mg once daily at steady state increased darifenacin Cmax and AUC by 88% and 84%, respectively Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex_biopharmr.pdf#page=46 Page: 46.0
BCRP 697	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21826715/	unresponsive
MRP 9	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21826715/	unresponsive
P-gp 2052	substrate 4014 Sources: https://onlinelibrary.wiley.com/doi/abs/10.1002/nau.21110	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex_pharmr.pdf#page=5 Page: 5.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:391960	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:391960
ChemicalBook	CB1506695	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1506695
MolPort	MolPort-005-943-011	https://www.molport.com/shop/molecule-link/MolPort-005-943-011
ZINC	ZINC000001996117	http://zinc15.docking.org/substances/ZINC000001996117

PubMed

Title	Date	PubMed
In vivo demonstration of M3 muscarinic receptor subtype selectivity of darifenacin in mice.	2006-12-14	16996089
Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?	2006-11	17021853
Darifenacin: Pharmacology and clinical usage.	2006-11	17011383
Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study.	2006-11	16879437
Public Relations: Ketchum brands new product with innovative PR strategy.	2006-10-20	17048759
Gateways to clinical trials.	2006-08-09	16894408
Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects.	2006-08	16687205
Regulation of bladder muscarinic receptor subtypes by experimental pathologies.	2006-07	16879497
[Oral anticholinergics in overactive bladder].	2006-07	16791627
[Anticholinergics for overactive bladder: does subtype selectivity play a role?].	2006-07	16767455
Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study.	2006-05	15999217
Gateways to clinical trials.	2006-04	16810345
Practical considerations of new drugs: new choices for old problems.	2006-04	16669748
The causes and consequences of overactive bladder.	2006-04	16620184
Gateways to clinical trials.	2006-03-17	16541195
Gateways to clinical trials.	2006-03	16636723
Management of overactive bladder and urge urinary incontinence in the elderly patient.	2006-03	16483866
Pharmacologic management of overactive bladder: practical options for the primary care physician.	2006-03	16483865
Using anticholinergics to treat overactive bladder: the issue of treatment tolerability.	2006-03	16483863
Muscarinic receptors in the bladder: from basic research to therapeutics.	2006-02	16465186
New drugs 06, part I.	2006-02	16462265
M2 and M3 muscarinic receptor activation of urinary bladder contractile signal transduction. II. Denervated rat bladder.	2006-02	16243962
M2 and M3 muscarinic receptor activation of urinary bladder contractile signal transduction. I. Normal rat bladder.	2006-02	16243961
Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB.	2006-01	16409440
Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder.	2006-01	16406943
Constitutive activity and inverse agonism at the M2 muscarinic acetylcholine receptor.	2006-01	16188951
The clinical pharmacokinetics of darifenacin.	2006	16584282
The Q-T interval and antimuscarinic drugs.	2005-11	16238912
Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers.	2005-11	16225528
Urodynamic effects of oxybutynin and tolterodine in conscious and anesthetized rats under different cystometrographic conditions.	2005-10-11	16216132
Gateways to clinical trials.	2005-10	16273137
Solifenacin in the management of the overactive bladder syndrome.	2005-10	16178992
Gateways to clinical trials.	2005-09	16258596
QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder.	2005-09	16100298
Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder.	2005-09	16096831
Role of muscarinic receptor antagonists in urgency and nocturia.	2005-09	16083453
Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist.	2005-09	15990219
Solifenacin and darifenacin for overactive bladder.	2005-08	16055596
Darifenacin in the treatment of overactive bladder.	2005-07	16193097
Effects of ageing on muscarinic receptor subtypes and function in rat urinary bladder.	2005-07	16059734
Darifenacin in the treatment of overactive bladder.	2005-07	15963212
Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow.	2005-07	15936869
Gateways to clinical trials.	2005-06	16082422
New treatment options for overactive bladder.	2005-06	16050656
Darifenacin: another antimuscarinic for overactive bladder.	2005-05	16548640
Solifenacin in overactive bladder syndrome.	2005	16363887
Overactive bladder in the elderly: a guide to pharmacological management.	2005	16363885
Contemporary and emerging drug treatments for urinary incontinence in children.	2005	15977961
Improving the tolerability of anticholinergic agents in the treatment of overactive bladder.	2005	15963006
[Overactive bladder].	2005	15912847

Patents

Sample Use Guides

In Vivo Use Guide

The recommended starting dose of darifenacin extended-release tablets (Enablex) is 7.5 mg once daily.

Route of Administration: Oral

In Vitro Use Guide

Bladder smooth muscle and submandibular gland cells isolated from Cynomolgus monkeys were treated with darifenacin and pKi values obtained in Ca2+ mobilization assay were 8,4 and 8,8, respectively.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 08:29:02 GMT 2025` Edited by `admin` on `Wed Apr 02 08:29:02 GMT 2025`
Record UNII	APG9819VLM
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

UK-88525

Preferred Name

English

DARIFENACIN

Official Name

English

3-PYRROLIDINEACETAMIDE, 1-(2-(2,3-DIHYDRO-5-BENZOFURANYL)ETHYL)-.ALPHA.,.ALPHA.-DIPHENYL-, (3S)-

Systematic Name

English

darifenacin [INN]

Common Name

English

2-((3S)-1-(2-(2,3-DIHYDROBENZOFURAN-5-YL)ETHYL)PYRROLIDIN-3-YL)-2,2-DIPHENYLACETAMIDE.

Common Name

English

DARIFENACIN [VANDF]

Common Name

English

Darifenacin [WHO-DD]

Common Name

English

UK88525

Code

English

DARIFENACIN [USAN]

Common Name

English

DARIFENACIN [MART.]

Common Name

English

DARIFENACIN EXTENDED RELEASE

Common Name

English

DARIFENACIN [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29704